These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15769928)

  • 61. Aromatase inhibitor and bone.
    Miki Y; Suzuki T; Sasano H
    Biomed Pharmacother; 2007 Oct; 61(9):540-2. PubMed ID: 17904790
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Cutaneous vasculitis due to hypersensitivity probably caused by ketorolac trometamol].
    Barroso Casamitjana E; Isla Tejera B; Ruano Ruiz J; Blanco-Molina A
    Farm Hosp; 2006; 30(1):60-2. PubMed ID: 16569187
    [No Abstract]   [Full Text] [Related]  

  • 63. Cutaneous leucocytoclastic vasculitis caused by cyclosporin A (Sandimmun).
    Gupta MN; Sturrock RD; Gupta G
    Ann Rheum Dis; 2000 Apr; 59(4):319. PubMed ID: 10787384
    [No Abstract]   [Full Text] [Related]  

  • 64. [Paradoxical cutaneous manifestations during anti-TNF-alpha therapy].
    Viguier M; Richette P; Bachelez H; Wendling D; Aubin F
    Ann Dermatol Venereol; 2010 Jan; 137(1):64-71; quiz 63, 78-9. PubMed ID: 20110075
    [No Abstract]   [Full Text] [Related]  

  • 65. Paracetamol-induced hypersensitivity vasculitis in a 10-year-old child.
    Guerriero C; Perino F; Favoriti N; Capizzi R; Sani I; Rigante D
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3405-6. PubMed ID: 24379075
    [No Abstract]   [Full Text] [Related]  

  • 66. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
    Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
    J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tamoxifen and purpuric vasculitis.
    Drago F; Arditi M; Rebora A
    Ann Intern Med; 1990 Jun; 112(12):965-6. PubMed ID: 2140253
    [No Abstract]   [Full Text] [Related]  

  • 69. Cutaneous vascular calcifications secondary to treatment with teriparatide.
    Leis-Dosil VM; Rubio-Flores C; Ruiz-Bravo Burguillos E; Díaz-Díaz RM
    Actas Dermosifiliogr; 2013 Jan; 104(1):87-8. PubMed ID: 22840755
    [No Abstract]   [Full Text] [Related]  

  • 70. Leucocytoclastic vasculitis and indinavir.
    Rachline A; Lariven S; Descamps V; Grossin M; Bouvet E
    Br J Dermatol; 2000 Nov; 143(5):1112-3. PubMed ID: 11069541
    [No Abstract]   [Full Text] [Related]  

  • 71. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
    Burstein HJ; Winer EP
    J Clin Oncol; 2007 Sep; 25(25):3797-9. PubMed ID: 17761968
    [No Abstract]   [Full Text] [Related]  

  • 72. Azathioprine and hypersensitivity vasculitis.
    Bergman SM; Krane NK; Leonard G; Soto-Aguilar MC; Wallin JD
    Ann Intern Med; 1988 Jul; 109(1):83-4. PubMed ID: 2967660
    [No Abstract]   [Full Text] [Related]  

  • 73. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Leukocytoclastic vasculitis associated with rivaroxaban.
    Sainz-Gaspar L; Pita da Veiga G; Suárez-Peñaranda JM; Vázquez-Veiga H; Sánchez-Aguilar D
    Int J Dermatol; 2018 May; 57(5):622-624. PubMed ID: 29460965
    [No Abstract]   [Full Text] [Related]  

  • 75. Unique Case of Urticarial Skin Eruptions After COVID-19 Vaccination.
    Baraldi C; Boling LB; Patrizi A; Prodi C; Deleonardi G; Gaspari V; Misciali C
    Am J Dermatopathol; 2022 Mar; 44(3):198-200. PubMed ID: 34291744
    [No Abstract]   [Full Text] [Related]  

  • 76. Urticarial vasculitis following cocaine use.
    Hofbauer GF; Hafner J; Trüeb RM
    Br J Dermatol; 1999 Sep; 141(3):600-1. PubMed ID: 10583098
    [No Abstract]   [Full Text] [Related]  

  • 77. Management of bone loss induced by aromatase inhibitors.
    Gnant M
    Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
    Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An Unusual Cause of Skin Rash in Crohn's Disease.
    Chebli JMF; de Oliveira Moreira B; da Rocha Ribeiro TC
    Gastroenterology; 2018 Sep; 155(3):618-620. PubMed ID: 29409941
    [No Abstract]   [Full Text] [Related]  

  • 80. Getting a grip on aromatase inhibitor-associated arthralgias.
    Hershman DL
    J Clin Oncol; 2008 Jul; 26(19):3120-1. PubMed ID: 18474872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.